# Theranos Whistleblower Warns AI Boom Facilitates Corporate Deception Tyler Shultz cautions that AI's complexity makes rigorous due diligence increasingly difficult for investors. - **Source:** [TechCrunch](https://techcrunch.com) - **Published:** 2026-10-30 - **Topic:** [Entrepreneurship](https://brifing.si/c/entrepreneurship) - **Original article:** - **On Brifing:** https://brifing.si/s/b225b7d4-928b-4071-8147-df578266d1d7 ## The Theranos Legacy Persists The documentary You Can See Everything examines Elizabeth Holmes' final days before prison, sparking national discourse. Despite the legal closure of the Theranos case, the fascination with her manipulative tactics remains high. Tyler Shultz, a key whistleblower who exposed the company's faulty blood testing technology, argues that Holmes actively cultivates this ongoing public attention. ## Scaling Deception to Millions Shultz criticizes the historical investment model where informal meetings led to massive capital injections. He notes that Holmes successfully scaled this approach to raise hundreds of millions. Investors often bypassed scientific verification, choosing to trust charismatic founders rather than demanding evidence that proprietary technology actually functioned as promised during the fundraising process. ## Due Diligence in AI The current AI boom presents a significant danger for investors who may be neglecting lessons learned from the Theranos fraud. Shultz highlights that performing due diligence on AI startups is exceptionally difficult. Distinguishing between genuinely unique, proprietary technology and simple wrappers built on existing models remains a major challenge for capital allocators. ## The Power of Capital When investors provide substantial funding to founders, they grant them immense power without always ensuring accountability. Theranos relied heavily on individual investors like the Walton and DeVos families rather than traditional venture firms. This structure allowed the company to withhold scientific data by citing trade secrets, effectively shielding their fraudulent operations from scrutiny. ## Theranos 2.0 Emerges Reports indicate that Elizabeth Holmes and her partner, Billy Evans, are currently developing a new diagnostics venture called Haemanthus. This entity has reportedly secured approximately $20 million in funding. Shultz expresses unease regarding this second act, noting that the public narrative often treats Holmes as a joke rather than a serious offender. ## The Pity Strategy The documentary suggests that Holmes intentionally invites media scrutiny to foster public pity. Shultz believes this calculated image management serves her future endeavors better than mockery or hate. By controlling the narrative, she attempts to reshape her persona, creating an environment where she can potentially launch new business ventures despite her past criminal convictions. ## Investment Risks Escalating As the industry enters the peak of the AI era, companies without profits are achieving trillion-dollar valuations. Shultz warns that the ease of raising capital in this environment invites bad actors to deceive people. The lack of transparency in AI development cycles mirrors the opacity that allowed Theranos to operate for years. ## Future Industry Outlook The intersection of high-stakes technology and cultural influence requires a more rigorous approach to investment. Shultz's warning serves as a reminder that technical verification must precede financial commitment. As the AI landscape matures, investors must prioritize objective evidence over founder charisma to avoid repeating the catastrophic failures of previous startup cycles. ## Sources covering this story - https://techcrunch.com/2026/10/30/theranos-whistleblower-tyler-shultz-warns-that-the-ai-boom-is-a-great-opportunity-to-go-deceive-people/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._